Q4 2025 Earnings Estimate for Travere Therapeutics, Inc. (NASDAQ:TVTX) Issued By Leerink Partnrs

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at Leerink Partnrs boosted their Q4 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a report released on Friday, October 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of $0.30 for the quarter, up from their prior forecast of $0.25. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.95) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). The business had revenue of $54.12 million during the quarter, compared to analysts’ expectations of $49.50 million. Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%.

A number of other research analysts have also weighed in on TVTX. Canaccord Genuity Group decreased their price target on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, September 30th. Barclays increased their price objective on Travere Therapeutics from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Tuesday, October 1st. Bank of America lifted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their target price on shares of Travere Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Citigroup lowered their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $19.75.

Travere Therapeutics Stock Up 6.3 %

Shares of TVTX opened at $17.44 on Monday. The company has a current ratio of 3.04, a quick ratio of 2.99 and a debt-to-equity ratio of 24.96. The stock’s 50 day moving average is $11.96 and its two-hundred day moving average is $9.05. The firm has a market cap of $1.33 billion, a P/E ratio of -8.30 and a beta of 0.73. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $18.60.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning increased its position in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company’s stock worth $335,000 after acquiring an additional 995 shares during the period. CWM LLC raised its position in Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares in the last quarter. Diversified Trust Co purchased a new position in shares of Travere Therapeutics in the 3rd quarter valued at about $161,000. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Travere Therapeutics by 203.0% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 615,000 shares of the company’s stock worth $5,055,000 after buying an additional 412,000 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Travere Therapeutics during the second quarter worth about $291,000.

Insider Activity

In other Travere Therapeutics news, CEO Eric M. Dube sold 21,125 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $243,360.00. Following the transaction, the chief executive officer now owns 361,975 shares of the company’s stock, valued at $4,169,952. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Travere Therapeutics news, SVP William E. Rote sold 4,387 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $50,538.24. Following the completion of the transaction, the senior vice president now directly owns 84,455 shares of the company’s stock, valued at $972,921.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Eric M. Dube sold 21,125 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $243,360.00. Following the sale, the chief executive officer now directly owns 361,975 shares in the company, valued at $4,169,952. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 110,707 shares of company stock valued at $1,504,312 in the last quarter. Insiders own 3.75% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.